

Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacogenetics in the clinical use of proton pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. *Aliment Pharmacol Ther.* 2003;17:1521-1528.

Fennerty MB. Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment. *Gastroenterol Clin North Am.* 1999;28:861-873.

Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for *Helicobacter pylori*. *Aliment Pharmacol Ther* 2007; 26:343.

Franko TG, Richter JE. Proton-pump inhibitors for gastric acid-related disease. *Cleve Clin J Med.* 1998;65:27-34.

Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *New Engl J Med* 1998; 338: 1397-404.

Gudipati Edukondalu, Mahaboob.Subhani. D. Nunna.Bhaskar Raju, Ashok Kumar varma, Rambabu Kuchi. A Novel RP-HPLC Method For The Quantification Of Tadalafil In Formulation Rambabu.Kuchi et al, *Research Desk*, 2012, Oct-Dec, 1(2).66-73 ISSN 2319-7315.